Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Saved in:
| Title: | Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV. |
|---|---|
| Authors: | Klausen U; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Grauslund JH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Jørgensen NGD; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Ahmad SM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Jonassen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Pedersen LB; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Lisle TL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Gang AO; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Enggaard L; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Pedersen LM; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Nov 22; Vol. 12, pp. 1023015. Date of Electronic Publication: 2022 Nov 22 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
